Benzinga | Jan 31, 2022 06:47AM EST

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $73

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $75 to $73.